Ocugen (OCGN) is climbing 5% after investment bank H.C. Wainwright raised its price target on the shares to $8 from $7. OCGN, ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

TOKYO -- Japanese researchers from Keio University and elsewhere announced Thursday that they have begun a clinical trial on a gene therapy to restore light sensitivity in patients with retinitis ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

Neuropsychiatric disorders are becoming increasingly prevalent. Given their complex and multifactorial pathogenesis, there is ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...

From Theresa Caputo to Amy and Joey and our unmistakable accent, Long Island has been the source of innumerable "SNL" gags ...

Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat ...

We recently published a list of 12 Best Italian Stocks to Buy in 2025. In this article, we are going to take a look at where ...